Tango Therapeutics, Inc.

Tango Therapeutics, Inc. (Nasdaq: TNGX) is a clinical-stage precision oncology company that completed its business combination with BCTG Acquisition Corp, a special purpose acquisition vehicle sponsored by Baker Bros. Advisors LP, and began trading under the TNGX ticker in 2021. BCTG Acquisition Corp completed its IPO in 2020, targeting the life sciences and biopharmaceutical sector. Tango Therapeutics focuses on discovering and developing cancer medicines through a synthetic lethality platform, leveraging genome-scale CRISPR functional genomics to identify tumor-specific vulnerabilities. The company filed its quarterly report on Form 10-Q with the SEC on August 9, 2021. Sign up at SpacDesk for full filings, deal timelines, and comprehensive SPAC research data.